Bimekizumab in Psoriatic Arthritis: 12-Month Retention, Multidomain Effectiveness, and Impact of Prior Interleukin-17 Inhibition in a Real-World Cohort

Joint Bone Spine · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles